Product Pathways - Tyrosine Kinase / Adaptors
SignalSilence® Met siRNA I #6618
|6618S||300 µl (3 nmol)||---||In Stock||---|
|6618||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-), SignalSilence® Met siRNA I (+) or SignalSilence® Met siRNA II #6622 (+), using Met (25H2) Mouse mAb #3127 (upper) or α-Tubulin (11H10) Rabbit mAb #2125 (lower). The Met (25H2) Mouse mAb confirms silencing of Met expression, while the α-Tubulin (11H10) Rabbit mAb is used to control for loading and specificity of Met siRNA.
SignalSilence® Met siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit Met expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions For Use
CST recommends transfection with 100 nM Met siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.
Met, a high affinity tyrosine kinase receptor for hepatocyte growth factor (HGF, also known as scatter factor) is a disulfide-linked heterodimer made of 45 kDa α- and 145 kDa β-subunits (1,2). The α-subunit and the amino-terminal region of the β-subunit form the extracellular domain. The remainder of the β-chain spans the plasma membrane and contains a cytoplasmic region with tyrosine kinase activity. Interaction of Met with HGF results in autophosphorylation at multiple tyrosines, which recruit several downstream signaling components, including Gab1, c-Cbl, and PI3 kinase (3). These fundamental events are important for all of the biological functions involving Met kinase activity. The addition of a phosphate at cytoplasmic Tyr1003 is essential for Met protein ubiquitination and degradation (4). Phosphorylation at Tyr1234/1235 in the Met kinase domain is critical for kinase activation. Phosphorylation at Tyr1349 in the Met cytoplasmic domain provides a direct binding site for Gab1 (5). Research studies have shown that altered Met levels and/or tyrosine kinase activities are found in several types of tumors, including renal, colon, and breast. Thus, investigators have concluded that Met is an attractive potential cancer therapeutic and diagnostic target (6,7).
- Cooper, C.S. et al. (1984) Nature 311, 29-33.
- Bottaro, D.P. et al. (1991) Science 251, 802-4.
- Bardelli, A. et al. (1997) Oncogene 15, 3103-11.
- Taher, T.E. et al. (2002) J Immunol 169, 3793-800.
- Schaeper, U. et al. (2000) J Cell Biol 149, 1419-32.
- Eder, J.P. et al. (2009) Clin Cancer Res 15, 2207-14.
- Sattler, M. and Salgia, R. (2009) Update Cancer Ther 3, 109-118.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
SignalSilence® is a trademark of Cell Signaling Technology, Inc.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.